Psoriasis Clinical Trial

Dupixent and Narrowband UVB for Atopic Dermatitis

Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

View Full Description

Full Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female adult ≥ 18 years of age;

Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

EASI score of 16 or greater,
IGA score of 3 or greater
BSA of 10% or greater,

Exclusion Criteria:

Subjects with previous exposure to dupilumab.
Known or suspected hypersensitivity to dupilumab or any of its excipients.
History of photosensitivity.

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

40

Study ID:

NCT05285839

Recruitment Status:

Recruiting

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Eczema Treatment Center of New Jersey
East Windsor New Jersey, 08520, United States More Info
Elise Nelson
Contact
609-443-4500
[email protected]
Jerry Bagel, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

40

Study ID:

NCT05285839

Recruitment Status:

Recruiting

Sponsor:


Psoriasis Treatment Center of Central New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.